ERRATUM: Determinant Factors of Clinical Outcome of Remdesivir for The Treatment of SARS-CoV-2 in Indonesia
Main Article Content
Abstract
Remdesivir is an antiviral approved for treating SARS-CoV-2 patients with moderate to severe symptoms. Remdesivir was effective in shortening the recovery time and preventing the severity of SARS-CoV-2 symptoms. This study aims to evaluate the clinical outcomes, side effects, and determinants that influence the clinical outcomes of remdesivir in treating patients with moderate to severe symptoms in Indonesia. An observational study with a cross-sectional design was conducted at a private hospital in East Java from October to December 2024. Retrospective data were collected through patient medical records and pharmacy reports. The WHO SARS-COV-2 seven-point ordinal clinical progression and recovery scale was used to measure patient clinical outcomes. Multivariate logistic regression analysis was performed to predict determinants of clinical outcomes. Ninety-one patients treated with remdesivir from January 2021 to December 2022 were included. This study found that the clinical outcome of patients who recovered or survived after remdesivir treatment was 52% (n=47). There was no significant improvement in clinical progression on days 1 and 6 among surviving patients (p=0.097). Tachycardia was the most common adverse event (n=58), followed by nausea (n=21) and bradycardia (n=18). Length of hospitalization (p=0.009), progression scale on day 1 of admission (p=0.001), and multivitamin medication (p=0.066) were all associated with patient clinical outcomes. The findings of this study highlight that remdesivir effectively prevents worse clinical progression. Longitudinal studies of post-remdesivir treatment in different locations are warranted.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
⦁ Allami RH, Hassoon AH,Abdulateef YM, Ghani AA. Genetic Association of Angiotensin-converting enzyme 2 ACE-2 (rs2285666) Polymorphism with the Susceptibility of COVID-19 Disease inIraqi Patients. Trop J Nat Prod Res. 2023; 7(2):2346-2351. Doi: 10.26538/tjnpr/v7i2.7 DOI: https://doi.org/10.26538/tjnpr/v7i2.7
⦁ Rajalakshmi S and Musthafa MM, Pharmacokinetics and Molecular Docking Study of Siddha Polyherbal Preparation ShailamAgainst COVID-19 Mutated s Gene.Trop J Nat Prod Res.2022; 6(4):502-513. Doi: 10.26538/tjnpr/v6i4.8
⦁ Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19):1813-1826. Doi: 10.1056/NEJMoa2007764 DOI: https://doi.org/10.1056/NEJMoa2007764
⦁ Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, Firdaus I, Santoso A, Juzar DA, Arif SK, Wulung NGHL, Muchtar F, Pulungan AB, Yanuarso PB, Sjakti HA, Prawira Y, Putri ND. Guideline for COVID-19 treatment (4th ed). Jakarta, Indonesia: The Indonesian Society of Respirology; 2022. 79-85 p.
⦁ Piscoya A, Ng-Sueng LF, Parra Del Riego A, Cerna-Viacava R. Pasupuleti V. Roman YM. Thota P. White CM. Hernandez AV. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. PLoS One. 2020; 15(12):e0243705. Doi:10.1371/journal.pone.0243705 DOI: https://doi.org/10.1371/journal.pone.0243705
⦁ Yusransyah Y, Udin B, Abdillah M, Murdianto Y, Soraya Uli E, Suryana N. Cost-Effectiveness Analysis in Covid-19 Patients Using Oxygen Therapy with and Without Remdesivir at Tangerang Regional Hospital. JFI. 2022; 14(1):17-24. Doi: 10.35617/jfionline.v14i1.75 DOI: https://doi.org/10.35617/jfionline.v14i1.75
⦁ Chen C, Fang J, Chen S, Rajaofera MJN, Li X, Wang B, Xia Q. The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2023; 23(1):672. Doi: 10.1186/s12879-023-08525-0 DOI: https://doi.org/10.1186/s12879-023-08525-0
⦁ Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, Metzendorf MI, Stegemann M, Benstoem C, Fichtner F. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021; 8(8):CD014962. Doi: 10.1002/14651858.CD014962 DOI: https://doi.org/10.1002/14651858.CD014962
⦁ Hung DT, Ghula S, Aziz JMA, Makram AM, Tawfik GM, Abozaid AA, Pancharatnam RA, Ibrahim AM, Shabouk MB, Turnage M, Nakhare S, Karmally Z, Kouz B, Le TN, Alhijazeen S, Phuong NQ, Ads AM, Abdelaal AH, Nam NH, Iiyama T, Kita K, Hirayama K, Huy NT. The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies. Int J Infect Dis. 2022; 120:217-227. Doi: 10.1016/j.ijid.2022.04.035 DOI: https://doi.org/10.1016/j.ijid.2022.04.035
⦁ Roche N, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, Antoniou KM, Ulrik CS, Parks H, Wang C, Vandendriessche T, Qu J, Stolz D, Brightling C, Welte T, Aliberti S, Simonds AK, Tonia T, Chalmers JD. Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2022; 60(2):2200803. Doi: 10.1183/13993003.00803-2022 DOI: https://doi.org/10.1183/13993003.00803-2022
⦁ Seo JW, Kim SE, Kim Y, Kim EJ, Kim T, Kim T, Lee SH, Lee E, Lee J, Seo YB, Jeong YH, Jung YH, Choi YJ, Song JY. Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID. Infect Chemother. 2024; 56(1):122-157. Doi: 10.3947/ic.2024.0024 DOI: https://doi.org/10.3947/ic.2024.0024
⦁ Lai CC, Chen CH, Wang CY, Chen KH, Wang YH, Hsueh PR. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2021; 76(8):1962-1968. Doi: 10.1093/jac/dkab093 DOI: https://doi.org/10.1093/jac/dkab093
⦁ Whittington MD, Pearson SD, Rind DM, Campbell JD. The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19. Value Health. 2022; 25(5):744-750. Doi: 10.1016/j.jval.2021.11.1378 DOI: https://doi.org/10.1016/j.jval.2021.11.1378
⦁ Burhan E, Syahruddin E, Isbaniah F, Desianti GA, Fachrucha F, Sari CYI, Ismail E, Astuti P, Maruli MF, Mubarak F, Rengganis AT, Bilqis HH, Taslim I, Sastria E, Wiyarta E. Evaluation of safety and effectiveness of remdesivir in treating COVID-19 patients after emergency use authorization study. Front Pharmacol. 2023; 14:1205238. Doi: 10.3389/fphar.2023.1205238 DOI: https://doi.org/10.3389/fphar.2023.1205238
⦁ Hadiatussalamah H, Andayani TM, Sari IP. Clinical outcome comparison of favipiravir and remdesivir in moderate COVID-19 patients at UGM academic hospital Yogyakarta. J Manag and Pharm Pract. 2023;13(3):175-185. ⦁ Doi: 10.22146/jmpf.84815 DOI: https://doi.org/10.22146/jmpf.84815
⦁ Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-1578. Doi: 10.1016/S0140-6736(20)31022-9 DOI: https://doi.org/10.1016/S0140-6736(20)31022-9
⦁ Sepandi M, Taghdir M, Alimohamadi Y, Afrashteh S, Hosamirudsari H. Factors Associated with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Iran. J. Public Health. 2020; 49(7):1211-1221. Doi: 10.18502/ijph.v49i7.3574 DOI: https://doi.org/10.18502/ijph.v49i7.3574
⦁ Hartantri Y, Debora J, Widyatmoko L, Giwangkancana G, Suryadinata H, Susandi E, Hutajulu E, Hakiman APA, Pusparini Y, Alisjahbana B. Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia. Lancet Reg Health Southeast Asia. 2023; 11:100167. Doi: 10.1016/j.lansea.2023.100167 DOI: https://doi.org/10.1016/j.lansea.2023.100167
⦁ Ohl ME, Miller DR, Lund BC, Kobayashi T, Richardson Miell K, Beck BF, Alexander B, Crothers K, Vaughan Sarrazin MS. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19. JAMA Netw Open. 2021; 4(7):e2114741. Doi: 10.1001/jamanetworkopen.2021.14741 DOI: https://doi.org/10.1001/jamanetworkopen.2021.14741
⦁ Poliseno M, Gallo C, Cibelli DC, Minafra GA, Bottalico IF, Bruno SR, D'Errico ML, Montemurro L, Rizzo M, Barbera L, Custodero GE, La Marca A, Lo Muzio D, Miucci A, Santantonio TA, Lo Caputo S. Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic. Antibiotics (Basel). 2021; 10(12):1477. Doi: 10.3390/antibiotics10121477 DOI: https://doi.org/10.3390/antibiotics10121477
⦁ Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020; 382(24):2327-2336. Doi: 10.1056/NEJMoa2007016 DOI: https://doi.org/10.1056/NEJMoa2007016
⦁ Shaikh Q, Sarfaraz S, Rahim A, Hussain M, Shah R, Soomro S. Effect of Remdesivir on mortality and length of stay in hospitalized COVID-19 patients: A single center study. Pak J Med Sci. 2022; 38(2):405-410. Doi: 10.12669/pjms DOI: https://doi.org/10.12669/pjms.38.ICON-2022.5779
⦁ Garibaldi BT, Wang K, Robinson ML, Zeger SL, Bandeen-Roche K, Wang MC, Alexander GC, Gupta A, Bollinger R, Xu Y. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. JAMA Netw Open. 2021; 4(3):e213071. Doi: 10.1001/jamanetworkopen.2021.3071 DOI: https://doi.org/10.1001/jamanetworkopen.2021.3071
⦁ Ramos-Rincon JM, López-Carmona MD, Cobos-Palacios L, López-Sampalo A, Rubio-Rivas M, Martín-Escalante MD, de-Cossio-Tejido S, Taboada-Martínez ML, Muiño-Miguez A, Areses-Manrique M, Martinez-Cilleros C, Tuñón-de-Almeida C, Abella-Vázquez L, Martínez-Gonzalez AL, Díez-García LF, Ripper CJ, Asensi V, Martinez-Pascual A, Guisado-Vasco P, Lumbreras-Bermejo C, Gómez-Huelgas R, On Behalf Of The Semi-Covid-Network. Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry. J Clin Med. 2022; 11(13):3769. Doi: 10.3390/jcm11133769 DOI: https://doi.org/10.3390/jcm11133769
⦁ Schulz A, Huynh N, Heger M, Bakir M. Adverse effects of remdesivir for the treatment of acute COVID-19 in the pediatric population: a retrospective observational study. Mol Cell Pediatr. 2024; 11(1):2. Doi: 10.1186/s40348-024-00175-9 DOI: https://doi.org/10.1186/s40348-024-00175-9
⦁ Terzić V, Miantezila Basilua J, Billard N, de Gastines L, Belhadi D, Fougerou-Leurent C, Peiffer-Smadja N, Mercier N, Delmas C, Ferrane A, Dechanet A, Poissy J, Espérou H, Ader F, Hites M, Andrejak C, Greil R, Paiva JA, Staub T, Tacconelli E, Burdet C, Costagliola D, Mentré F, Yazdanpanah Y, Diallo A; DisCoVeRy Study Group. Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial. Clin Infect Dis. 2024; 79(2):382-391. Doi: 10.1093/cid/ciae170 DOI: https://doi.org/10.1093/cid/ciae170
⦁ Ghahremanian A, Photography H, Ghasemi S, Heidari M, ghadrdan E. Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center. J. Pharm. Care. 2023; 11(3):145-150. Doi: ⦁ 10.18502/jpc.v11i3.15997 DOI: https://doi.org/10.18502/jpc.v11i3.15997
⦁ Dherange P, Lang J, Qian P, Oberfeld B, Sauer WH, Koplan B, Tedrow U. Arrhythmias and COVID-19: A Review. JACC Clin Electrophysiol. 2020; 6(9):1193-1204. Doi: 10.1016/j.jacep.2020.08.002 DOI: https://doi.org/10.1016/j.jacep.2020.08.002
⦁ Liaqat A, Zafar IA, Asad M, Alffenaar J. Evaluation of Clinical Outcomes After Remdesivir Therapy in Patients with Moderately Severe Covid-19 Disease. Prospective Study. Res Sq. 2022:1-13. Doi: 10.21203/rs.3.rs-1350373/v1 DOI: https://doi.org/10.21203/rs.3.rs-1350373/v1
⦁ Artifoni M, Danic G, Gautier G, Gicquel P, Boutoille D, Raffi F, Néel A, Lecomte R. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis. 2020; 50(1):211-216. Doi: 10.1007/s11239-020-02146-z DOI: https://doi.org/10.1007/s11239-020-02146-z
⦁ Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. Doi: 10.1016/S0140-6736(20)30566-3 DOI: https://doi.org/10.1016/S0140-6736(20)30566-3
⦁ Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, Goodarzi K, Bendapudi PK, Bornikova L, Gupta S, Leaf DE, Kuter DJ, Rosovsky RP. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020; 136(4):489-500. Doi: 10.1182/blood.2020006520. DOI: https://doi.org/10.1182/blood.2020006520
⦁ Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, Chen X, Chen S, Yu K, Huang Z, Hu B. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020; 8(49):1-13. Doi: 10.1186/s40560-020-00466-z DOI: https://doi.org/10.1186/s40560-020-00466-z
⦁ Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020; 18(6):1324-1329. Doi: 10.1111/jth.14859 DOI: https://doi.org/10.1111/jth.14859
⦁ Song X, Ji J, Reva B, Joshi H, Calinawan AP, Mazumdar M, Wisnivesky JP, Taioli E, Wang P, Veluswamy RR. Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality. ERJ Open Res. 2021; 7(3):00018-2021. Doi: 10.1183/23120541.00018-2021 DOI: https://doi.org/10.1183/23120541.00018-2021
⦁ Setiadi F, Panjaitan DA, Aviatin M. Effect of Anticoagulant Use on Reducing D-Dimer in COVID-19 Patients. The Indonesian J Infect Dis. 2022; 8(2):30-34. Available from: https://ijid-rspisuliantisaroso.co.id/index.php/ijid/article/view/149 DOI: https://doi.org/10.32667/ijid.v8i2.149
⦁ Langford BJ, So M, Raybardhan S, Leung V, Soucy JPR, Westwood D, Daneman N, MacFadden DR. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. ⦁ Clin Microbiol Infect. 2021; 27(4):520-531. Doi:10.1016/j.cmi.2020.12.018 DOI: https://doi.org/10.1016/j.cmi.2020.12.018
⦁ Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Møller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021; 47(11):1181-1247. Doi: 10.1007/s00134-021-06506-y DOI: https://doi.org/10.1007/s00134-021-06506-y
⦁ Jiang L, Li Y, Du H, Qin Z, Su B. Effect of Anticoagulant Administration on the Mortality of Hospitalized Patients With COVID-19: An Updated Systematic Review and Meta-
Analysis. Front Med (Lausanne). 2021; 8:698935. Doi: 10.3389/fmed.2021.698935 DOI: https://doi.org/10.3389/fmed.2021.698935
⦁ Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(5):1023-1026. Doi: 10.1111/jth.14810 DOI: https://doi.org/10.1111/jth.14810
⦁ Soroush Y, Esmaily H, Ghalandari N. The evaluation of Remdesivir Utilization pattern and its correlation with clinical indicators in hospitalized patients during COVID. J Pharm Care. 2023; 11(4):226-232. Doi: ⦁ 10.18502/jpc.v11i4.16020
⦁ Platzer M, Totschnig D, Karolyi M, Clodi-Seitz T, Wenisch C, Zoufaly A. The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients. Wien Klin Wochenschr. 2024; 136(15-16):458-464. Doi: 10.1007/s00508-024-02377-7 DOI: https://doi.org/10.1007/s00508-024-02377-7
⦁ Ryu BH, Lee JY, Lee SH. The effect of early versus late remdesivir treatment in hospitalized mild to moderate COVID-19 patients in the Omicron era: A retrospective study. Medicine (Baltimore). 2024; 103(29):e39035. Doi: 10.1097/MD.0000000000039035 DOI: https://doi.org/10.1097/MD.0000000000039035
⦁ Razzack AA, Hassan SA, Pasya SKR, Erasani G, Kumar S, Rocha-Castellanos DM, Lopez-Mendez A, Razzack SA. A Meta-Analysis of Association between Remdesivir and Mortality among Critically-Ill COVID-19 Patients. Infect Chemother. 2021; 53(3):512-518. Doi: 10.3947/ic.2021.0060 DOI: https://doi.org/10.3947/ic.2021.0060
⦁ Terkes V, Lisica K, Marusic M, Verunica N, Tolic A, Morovic M. Remdesivir Treatment in Moderately Ill COVID-19 Patients: A Retrospective Single Center Study. J Clin Med. 2022; 11(17):5066. Doi: 10.3390/jcm11175066 DOI: https://doi.org/10.3390/jcm11175066
⦁ Anekwe L. Daily multivitamins do not protect against cardiovascular events, finds study. BMJ. 2012; 345:e7599. Doi: 10.1136/bmj.e7599 DOI: https://doi.org/10.1136/bmj.e7599
⦁ Lehrer S, Rheinstein PH. Common drugs, vitamins, nutritional supplements and COVID-19 mortality. Int J Funct Nutr. 2021; 2(1):4. Doi: 10.3892/ijfn.2021.14 DOI: https://doi.org/10.3892/ijfn.2021.14
⦁ Speeckaert MM, Delanghe JR. Association of Vitamin D Status and COVID-19-Related Hospitalization and Mortality. J Gen Intern Med. 2022; 37(13):3491-3492. Doi: 10.1007/s11606-022-07658-3 DOI: https://doi.org/10.1007/s11606-022-07658-3
⦁ Speakman LL, Michienzi SM, Badowski ME. Vitamins, supplements and COVID-19: a review of currently available evidence. Drugs Context. 2021; 10:2021-6-2. Doi: 10.7573/dic.2021-6-2 DOI: https://doi.org/10.7573/dic.2021-6-2
⦁ Huang C, Lu T-L, Lin L. Remdesivir Treatment Lacks the Effect on Mortality Reduction in Hospitalized Adult COVID-19 Patients Who Required High-Flow Supplemental Oxygen or Invasive Mechanical Ventilation. Medicina. 2023; 59(6):1027. Doi: 10.3390/medicina59061027 DOI: https://doi.org/10.3390/medicina59061027
⦁ Beran A, Mhanna M, Assaly R. Reply to letter to the editor to "clinical significance of micronutrient supplements in patients with coronavirus disease 2019: A comprehensive systematic review and meta-analysis". Clin. Nutr. ESPEN. 2023; 54:461-462. Doi: 10.1016/j.clnesp.2022.12.003 DOI: https://doi.org/10.1016/j.clnesp.2022.12.003
⦁ Rista, UN, Setyowati, D, Julaeha J. Potential Drug-Induced Liver Injury (Dili) Event During Remdesivir Treatment in Covid-19 Patients. In Proceedings of the 3rd International Seminar and Call for Paper (ISCP) UTA '45 Jakarta - ISCP UTA'45 Jakarta; ISBN 978-989-758-654-5; ISSN 2828-853X, SciTe Press, 2023;372-375. Doi: 10.5220/0012025400003582 DOI: https://doi.org/10.5220/0012025400003582